Genetic Regulation of Immune Responses to Vaccines in Early Life
Overview
Affiliations
Infant immunization is the most cost-effective strategy to prevent infectious diseases in childhood, but is limited by immaturity of the immune system. To define strategies to improve vaccine immunogenicity in early life, the role of genetic and environmental factors in the control of vaccine responses in infant twins was studied. Immune responses to BCG, polio, hepatitis B, diphtheria, pertussis and tetanus vaccines were measured at 5 months of age in 207 Gambian twin pairs recruited at birth. Intrapair correlations for monozygous and dizygous pairs were compared to estimate the environmental and genetic components of variation in responses. High heritability was observed for antibody (Ab) responses to hepatitis B (77%), oral polio (60%), tetanus (44%) and diphtheria (49%) vaccines. Significant heritability was also observed for interferon-gamma and interleukin-13 responses to tetanus, pertussis and some BCG vaccine antigens (39-65%). Non-HLA genes played a dominant role in responses to Ab-inducing vaccines, whereas responses to BCG were predominantly controlled by genes within the HLA class II locus. Genetic factors, particularly non-HLA genes, significantly modulate immune responses to infant vaccination. The identification of the specific genes involved will provide new targets for the development of vaccines and adjuvants for young infants that work independently of HLA.
Smatti M, Yassine H, Mbarek H, Boomsma D Genes (Basel). 2025; 16(2).
PMID: 40004506 PMC: 11855666. DOI: 10.3390/genes16020177.
Tuberculosis vaccines and therapeutic drug: challenges and future directions.
An Y, Ni R, Zhuang L, Yang L, Ye Z, Li L Mol Biomed. 2025; 6(1):4.
PMID: 39841361 PMC: 11754781. DOI: 10.1186/s43556-024-00243-6.
Vaccinomics: Paving the Way for Personalized Immunization.
Al-Eitan L, ElMotasem M, Khair I, Alahmad S Curr Pharm Des. 2024; 30(13):1031-1047.
PMID: 38898820 DOI: 10.2174/0113816128280417231204085137.
Vaccinomics and adversomics: key elements for a personalized vaccinology.
Lagana A, Visalli G, Di Pietro A, Facciola A Clin Exp Vaccine Res. 2024; 13(2):105-120.
PMID: 38752004 PMC: 11091437. DOI: 10.7774/cevr.2024.13.2.105.
Blake J, Thompson J, HogenEsch H, Ekenstedt K Vaccine. 2024; 42(12):3099-3106.
PMID: 38604911 PMC: 11144447. DOI: 10.1016/j.vaccine.2024.03.076.